Navellier & Associates Inc. purchased a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 178,745 shares of the biotechnology company's stock, valued at approximately $3,065,000. Navellier & Associates Inc. owned 0.08% of ADMA Biologics at the end of the most recent reporting period.
Other hedge funds have also recently bought and sold shares of the company. Hollencrest Capital Management bought a new stake in shares of ADMA Biologics in the 3rd quarter worth about $30,000. Larson Financial Group LLC acquired a new stake in shares of ADMA Biologics during the third quarter worth approximately $31,000. GAMMA Investing LLC raised its stake in shares of ADMA Biologics by 106.6% in the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock valued at $32,000 after acquiring an additional 967 shares during the last quarter. National Bank of Canada FI acquired a new position in shares of ADMA Biologics in the 3rd quarter worth approximately $35,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in shares of ADMA Biologics in the 3rd quarter worth approximately $62,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.
ADMA Biologics Price Performance
ADMA stock traded down $0.03 during midday trading on Monday, reaching $15.81. The company had a trading volume of 824,371 shares, compared to its average volume of 2,244,676. The company has a market capitalization of $3.74 billion, a price-to-earnings ratio of 56.54 and a beta of 0.75. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. ADMA Biologics, Inc. has a 1-year low of $5.08 and a 1-year high of $23.64. The stock has a 50 day moving average price of $16.97 and a 200-day moving average price of $18.00.
Analyst Upgrades and Downgrades
A number of equities analysts have commented on the company. HC Wainwright boosted their price objective on ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a research note on Friday, November 8th. Raymond James increased their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a report on Friday, November 8th.
Get Our Latest Research Report on ADMA Biologics
About ADMA Biologics
(
Free Report)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
See Also
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
